MeVis Medical Solutions AG

Transaction in Own Shares • Mar 4, 2008

News Details

Ad-hoc | 4 March 2008 15:53

MeVis Medical Solutions launching stock buy-back program

MeVis Medical Solutions AG / Share Buyback

Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---

MeVis Medical Solutions launching stock buy-back program

Bremen, March 04, 2008. Bremen-based MeVis Medical Solutions AG [ISIN
DE000A0LBFE4], a specialist in disease-oriented software products for
image-based medicine, is launching a stock buy-back program. Under a
resolution passed at the annual general meeting on September 28, 2007, the
Company is authorized to buy back up to ten percent of its own current
share capital in accordance with Section 71 (1) No. 8 of the German Stock
Corporations Act. MeVis Medical Solutions already holds 37,800 treasury
shares. The Management Board decided on March 4, 2008 to initially buy back
a further volume of up to 53,200 of the Company’s own shares via the stock
market by August 30 of this year. Together with the existing treasury
stock, MeVis Medical Solutions will hold up to five percent of its own
shares by the end of the stock buy-back program.

The Management Board takes the view that MeVis Medical Solutions stock is
not appropriately valued at its current price. By buying back its own
stock, the Company wants to gain additional strategic scope in the event of
acquisitions, the purchase of intellectual property, investments and
similar transactions aimed at implementing its growth strategy. If it is
not possible for these transactions to be realized in the foreseeable
future, the treasury stock can also be cancelled.

The buyback is being executed by M.M.Warburg & CO in accordance with the
provisions of EU Regulation 2273/2003 of December 22, 2003 independently
and free of any influence on the part of the Company. In accordance with
the wording of the resolution passed by the shareholders at the annual
general meeting, the purchase price of the shares (excluding transactions
costs) must not be any more than five percent above or below the average
price at which the Company’s stock has been trading in the closing auction
of the Frankfurt stock exchange Xetra trading system on the five trading
days immediately preceding the acquisition.

Information on the progress of the stock buy-back program will be regularly
updated at MeVis Medical Solution AG’s website.

Company contact:
MeVis Medical Solutions AG
Dr. Olaf Sieker, CFO
Tel: +49 421 22495-36
E-Mail: olaf.sieker@mevis.de

Press and Investor Relations:
HOSCHKE & CONSORTEN Public Relations GmbH
Fabian Lorenz, Grit Pauli
Tel: +49 40 3690 50-56 / -31
E-Mail: f.lorenz@hoschke.de; g.pauli@hoschke.de

04.03.2008 Financial News transmitted by DGAP

Language: English
Issuer: MeVis Medical Solutions AG
Universitätsallee 29
28359 Bremen
Deutschland
Phone: +49 421 330 74-0
Fax: +49 421 330 74-50
E-mail: office.mms@mevis.de
Internet: http://www.mevis.de
ISIN: DE000A0LBFE4
WKN: A0LBFE
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Stuttgart, München, Düsseldorf

End of News DGAP News-Service

---